BACKGROUND: Changes in quality of life (QoL) after catheter ablation for long-standing persistent atrial fibrillation (LSPAF) are not well described. We sought to compare QoL improvement after catheter ablation of paroxysmal atrial fibrillation (PAF) versus that after LSPAF. METHODS AND RESULTS: A total of 261 PAF and 126 LSPAF ablation recipients were prospectively followed for arrhythmia recurrence, QoL, hospital stay, and sick leave. In PAF versus LSPAF groups, 1.3±0.6 versus 1.6±0.7 procedures were performed per patient (P<0.00001) during a 3-year follow-up. Good arrhythmia control was achieved in 86% versus 87% of patients (P=0.69) and in 69% versus 69% of patients not receiving antiarrhythmic drugs (P=0.99). The baseline QoL was better in the PAF than in the LSPAF group (European Quality of Life Group instrument self-report questionnaire visual analog scale: 66.4±14.2 versus 61.0±14.2, P=0.0005; European Quality of Life Group 3-level, 5-dimensional descriptive system: 71.4±9.2 versus 67.7±13.8, P=0.002). Postablation 3-year increase in QoL was significant in both groups (all P<0.00001) and significantly lower in PAF versus LSPAF patients (visual analog scale: +5.0±14.5 versus +10.2±12.8, P=0.001; descriptive system: +5.9±14.3 versus +9.3±13.9, P=0.03). In multivariate analysis, LSPAF, less advanced age, shorter history of AF and good arrhythmia control were consistently associated with postablation 3-year improvement in QoL. Days of hospital stay for cardiovascular reasons and days on sick leave per patient/year were significantly reduced in both groups. CONCLUSIONS: Patients with LSPAF had worse baseline QoL. The magnitude of QoL improvement after ablation of LSPAF was significantly greater compared with after ablation of PAF, particularly when good arrhythmia control was achieved without the use of antiarrhythmic drugs.

Department of Cardiology and Angiology 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Cardiology and Angiology St Anne's University Hospital and International Clinical Research Center Brno Czech Republic

Department of Cardiology Hospital Podlesí Třinec Czech Republic

Department of Internal Medicine and Cardiology University Hospital Masaryk University Brno Czech Republic

Zobrazit více v PubMed

European Heart Rhythm Association, European Association for Cardio‐Thoracic Surgery. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al‐Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kohl P, Le Heuzy JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31:2369-2429. PubMed

Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haïssaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jaïs P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow‐up, definitions, endpoints, and research trial design. Heart Rhythm. 2012; 9:632-696. PubMed

Weerasooriya R, Jaïs P, Hocini M, Scavee C, Macle L, Hsu LF, Sanders P, Garrigue S, Clementy J, Haïssaguerre M. Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. Heart Rhythm. 2005; 2:619-623. PubMed

Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash W, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo S, Bonso A, Natale A. Radiofrequency ablation vs. antiarrhythmic drugs as first‐line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005; 293:2634-2640. PubMed

Jaïs P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, Hocini M, Extramiana F, Sacher F, Bordachar P, Klein G, Weerasooriya R, Clémenty J, Haïssaguerre M. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation. Circulation. 2008; 118:2498-2505. PubMed

Pappone C, Vicedomini G, Augello G, Mantiso F, Savano M, Baldi M, Petretta A, Giannelli L, Calovic Z, Filuta V, Tavazzi L, Santinelli V. Radiofrequency catheter ablation and antiarrhythmic drug therapy. A prospective, randomized, 4‐year follow‐up trial: the APAF Study. Circ Arrhythm Electrophysiol. 2011; 4:808-814. PubMed

Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, Bradley DJ, Blum CM, Haroldson JM, Packer DL. Long‐term quality of life after ablation of atrial fibrillation. The impact of recurrence, symptom relief, and placebo effect. J Am Coll Cardiol. 2010; 55:2308-2316. PubMed

Reynolds MR, Walczak J, White SA, Cohen DJ, Wilber DJ. Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes. 2010; 3:615-623. PubMed

Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr, Bates ER, Lehmann MH, Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F. Circumferential pulmonary‐vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354:934-941. PubMed

Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004; 351:2373-2383. PubMed

Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman‐Haley SL, McDonagh TA, Underwood R, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013; 61:1894-1903. PubMed

Fiala M, Wichterle D, Bulková V, Škňouřil L, Nevřalová R, Toman O, Dorda M, Januška J, Špinar J. A prospective evaluation of hemodynamics, functional status, and quality of life after radiofrequency catheter ablation of long‐standing persistent atrial fibrillation. Europace. 2014; 16:15-25. PubMed

Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F. A single European currency for EQ‐5D health states. Results from a six country study. Eur J Health Econ. 2003; 4:222-231. PubMed

Rostock T, Salukhe TV, Steven D, Drewitz I, Hoffmann BA, Bock K, Servatius H, Müllerleile K, Sultan A, Gosau N, Meinertz T, Wegsheider K, Willems S. Long‐term single‐ and multiple‐procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. Heart Rhythm. 2011; 8:1391-1397. PubMed

Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010; 3:32-38. PubMed

Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, Sacher F, Lellouche N, Knecht S, Wright M, Nault I, Miyazaki S, Scavee C, Clementy J, Haïssaguerre M. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow‐up? J Am Coll Cardiol. 2011; 57:160-166. PubMed

Grönefeld GC, Lilienthal J, Kuck KH, Hohloser SHfor the Pharmacological Intervention in Atrial Fibrillation (PIAF) Study Investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J. 2003; 24:1430-1436. PubMed

Hagens VE, Ranchor AV, Sonderen EV, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder ICfor the RACE Study Group. Effect of rate or rhythm control on quality of life in persistent AF. J Am Coll Cardiol. 2004; 43:241-247. PubMed

Singh SN, Tang XC, Singh BN, Dorian P, Reda DJ, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD, Lopez B, Raisch DW, Ezekowitz MDfor SAFE‐T Investigators. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol. 2006; 48:721-730. PubMed

Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P, Gulletta S, Gugliotta F, Pappone A, Santinelli V, Tortoriello V, Sala S, Zangrillo A, Crescenzi G, Benussi S, Alfieri O. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long‐term study. J Am Coll Cardiol. 2003; 42:185-197. PubMed

Kleinman NL, Rohrbacker NJ, White SA, March JL, Reynolds MR. Economic impact to employers of treatment options for cardiac arrhythmias in the US health system. J Occup Environ Med. 2011; 53:405-414. PubMed

Quercioli C, Mesina G, Barbini E, Carriero G, Fani M, Nante N. Importance of sociodemographic and morbidity aspects in measuring health‐related quality of life: performance of three tools. Eur J Health Econ. 2009; 10:389-397. PubMed PMC

Catheter ablation for non-paroxysmal atrial fibrillation. A review

Catheter Ablation for Persistent and Long-Standing Persistent Atrial Fibrillation